LivaNova (LIVN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

LivaNova

NasdaqGS•Healthcare•Medical Devices

$78.51-0.96(-0.01%)Pre-market

Market Cap

$4.28B

P/E

22.7x

P/S

2.9x

P/B

3.2x

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.

How this company scores

ExcellentMetricSide Score: 85/100

Strongest: Balance Sheet & Red Flags (24/25); weakest: Cash & Earnings Quality (18/25).

Profitability21/25

Growth22/25

Balance Sheet & Red Flags24/25

Cash & Earnings Quality18/25

Strengths

Rising earningsLow leverageCash-backed earningsConsistent free cash flow

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 22.7x5y range 22.7x – 995.4x

Currently below its 6-quarter median.

P/S · 2.9x5y range 1.7x – 4.1x

Currently near its 20-quarter median.

P/B · 3.2x5y range 1.9x – 3.4x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $4.28B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.47B
Q. Revenue: $390.59M
TTM EBITDA: $240.14M
TTM Op. Income: $187.54M
Q. Op. Income: $49.48M
TTM Net Income: $188.55M
Q. Net Income: $108.57M
EPS: $1.98
Shares Out.: $54.97M

$1.47B in TTM revenue grew 12.4% YoY, reaching $390.59M last quarter. TTM EBITDA of $240.14M and TTM operating income of $187.54M show growth is flowing through to the bottom line. TTM net income of $188.55M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 70.1%
EBITDA Margin: 16.6%
Op. Margin: 12.7%
Net Margin: 27.8%

Op. margin of 12.7% is down 2.7% YoY — costs are rising relative to revenue. Net margin at 27.8% and gross margin of 70.1% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 18% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 22.7x
P/S Ratio: 2.9x
P/B Ratio: 3.2x

At 22.7x P/E, the stock trades within typical market levels. P/S of 2.9x and P/B of 3.2x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 4 quarters, P/E has fallen for 3 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $2.64B
Cash: $516.62M
Long-Term Debt: $289.91M
Book Value: $1.33B
D/E Ratio: 0.2
Debt/EBITDA: 4.5

With $2.64B in assets and $289.91M in long-term debt, D/E is 0.2and book value is $1.33B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 5 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $66.59M
TTM Free Cash Flow: $148.31M
FCF Margin: 10.1%
FCF / Net Income: 0.8

TTM FCF of $148.31M on $66.59M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 3 consecutive quarters — a weakening trend.